SLNO - Soleno Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

SLNO is currently covered by 8 analysts with an average price target of $111.53. This is a potential upside of $36.31 (48.27%) from yesterday's end of day stock price of $75.22.

Soleno Therapeutics's activity chart (see below) currently has 8 price targets and 45 ratings on display. The stock rating distribution of SLNO is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 59.75% with an average time for these price targets to be met of 128.25 days.

Highest price target for SLNO is $145, Lowest price target is $73, average price target is $102.75.

Most recent stock forecast was given by DEBJIT CHATTOPADHYAY from GUGGENHEIM on 08-May-2025. First documented stock forecast 22-Jun-2018.

Currently out of the existing stock ratings of SLNO, 37 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$97

$23.65 (32.24%)

$81

28 days ago
(08-May-2025)

2/4 (50%)

$20.74 (27.20%)

31

Buy

$105

$31.65 (43.15%)

$102

28 days ago
(08-May-2025)

2/4 (50%)

$28.74 (37.69%)

224

Buy

$145

$71.65 (97.68%)

$93

1 months 12 days ago
(24-Apr-2025)

0/3 (0%)

$70.77 (95.34%)

Buy

$100

$26.65 (36.33%)

$100

1 months 21 days ago
(15-Apr-2025)

4/6 (66.67%)

$29.75 (42.35%)

121

Buy

$123

$49.65 (67.69%)

$67

2 months 9 days ago
(27-Mar-2025)

6/7 (85.71%)

$55.61 (82.52%)

111

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is SLNO (Soleno Therapeutics) average time for price targets to be met?

On average it took 128.25 days on average for the stock forecasts to be realized with a an average price target met ratio 59.75

Which analyst has the current highest performing score on SLNO (Soleno Therapeutics) with a proven track record?

BRIAN SKORNEY

Which analyst has the current lower performing score on SLNO (Soleno Therapeutics) with a proven track record?

YASMEEN RAHIMI

Which analyst has the most public recommendations on SLNO (Soleno Therapeutics)?

Brian Skorney works at BAIRD and has 9 price targets and 5 ratings on SLNO

Which analyst is the currently most bullish on SLNO (Soleno Therapeutics)?

Yasmeen Rahimi with highest potential upside - $71.65

Which analyst is the currently most reserved on SLNO (Soleno Therapeutics)?

Leland Gershell with lowest potential downside - -$0.35

Soleno Therapeutics in the News

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025

Soleno Therapeutics REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its VYKATTM XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, clinical development program for the treatment...

Soleno Therapeutics Inc (SLNO) Q1 2025 Earnings Call Highlights: Navigating Early Success and ...

Cash Used in Operating Activities: $32.8 million for the three months ended March 31, 2025. Ending Cash, Cash Equivalents, and Marketable Securities: $290 million as of March 31, 2025. Research and Development Expenses: $13.5 million for Q1 2025, including $4.3 million of noncash stock-based compensation. Selling, General, and Administrative Expenses: $29.3 million for Q1 2025,...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?